t
IXICO plc announced on January 25, 2024, that all resolutions put forward at its Annual General Meeting were duly passed. These resolutions included the re-election of Mark Warne, the election of Dipti Amin, and the appointment of Moore Kingston Smith as auditors. Votes in favour of the resolutions ranged from 99.80% to 99.92%, with 43.08% to 43.11% of the Issued Share Capital being voted.
| Date | 25 Jan 2024 |
| Time | 16:00:00 |
| Category | AGMs and other meetings |
| ID | 9610A |
25 January 2024
IXICO plc
("IXICO" or the "Company")
Results of AGM
IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering insights in neuroscience announces that all resolutions put forward to its Annual General Meeting held earlier today were duly passed and the votes cast were as follows:
|
|
RESOLUTION |
VOTES |
% |
VOTES |
% |
VOTES |
% ISC VOTED |
VOTES |
|
1 |
Reports and Accounts
|
20,820,635 |
99.92% |
16,913 |
0.08% |
20,837,548 |
43.10 |
7,409 |
|
2a |
Re-election of Mark Warne
|
20,811,026 |
99.87% |
26,948 |
0.13% |
20,837,974 |
43.10 |
6,983 |
|
2b |
Election of Dipti Amin |
20,814,152 |
99.92% |
17,113 |
0.08% |
20,831,265 |
43.08 |
13,692 |
|
3 |
Appointment of Moore Kingston Smith Auditors |
20,819,713 |
99.88% |
24,122 |
0.12% |
20,843,835 |
43.11 |
1,122 |
|
4 |
Allotment of Securities
|
20,819,913 |
99.89% |
23,822 |
0.11% |
20,843,735 |
43.11 |
1,222 |
|
5 |
* Disapply Pre-Emption Provisions |
20,800,863 |
99.80% |
42,572 |
0.20% |
20,843,435 |
43.11 |
1,522 |
* Special Resolution
Please note that a 'vote withheld' is not a vote under English Law and is not counted in the calculation
of the proportion of the votes 'for' and 'against' a resolution.
For further information please contact:
|
IXICO plc |
+44 (0) 20 3763 7499 |
|
|
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer |
|
|
|
|
|
|
|
Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker) |
+44 (0) 20 7220 0500 |
|
|
Giles Balleny / Dan Hodkinson (Corporate Finance) Michael F Johnson / Tamar Cranford Smith (Sales) |
|
|
About IXICO
IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.
IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.
More information is available on www.IXICO.com and follow us on Twitter @IXICOnews